Sana Biotechnology (NASDAQ:SANA) Shares Up 7.8% – Still a Buy?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) shot up 7.8% on Friday . The stock traded as high as $3.51 and last traded at $3.5150. 550,561 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 3,184,175 shares. The stock had previously closed at $3.26.

Analyst Ratings Changes

Several equities analysts have commented on the company. HC Wainwright lowered their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Rodman & Renshaw assumed coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price target for the company. Zacks Research cut shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Sunday, June 7th. Finally, Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.50.

Sana Biotechnology Price Performance

The stock has a 50 day simple moving average of $3.20 and a 200-day simple moving average of $3.71. The firm has a market cap of $951.75 million, a PE ratio of -3.68 and a beta of 2.14.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. As a group, equities analysts predict that Sana Biotechnology, Inc. will post -0.59 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after buying an additional 1,375,029 shares in the last quarter. Integral Health Asset Management LLC increased its position in shares of Sana Biotechnology by 33.3% during the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after acquiring an additional 500,000 shares in the last quarter. Rafferty Asset Management LLC bought a new stake in shares of Sana Biotechnology during the third quarter valued at approximately $951,000. Rockefeller Capital Management L.P. raised its holdings in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after acquiring an additional 4,088 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Sana Biotechnology by 32.4% in the 1st quarter. SG Americas Securities LLC now owns 130,083 shares of the company’s stock worth $375,000 after acquiring an additional 31,796 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.